Apellis Pharmaceuticals, Inc. (APLS)
26.04
+0.92
(+3.66%)
USD |
NASDAQ |
Jan 02, 11:47
Apellis Pharmaceuticals Cash from Investing (Quarterly): -0.148M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biogen, Inc. | -35.10M |
| Amicus Therapeutics, Inc. | -1.299M |
| Fortress Biotech, Inc. | 2.87M |
| Ultragenyx Pharmaceutical, Inc. | 117.18M |
| Fulcrum Therapeutics, Inc. | 18.61M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 108.47M |
| Cash from Financing (Quarterly) | 0.793M |
| Free Cash Flow | 78.64M |
| Free Cash Flow Per Share (Quarterly) | 0.8328 |
| Free Cash Flow to Equity (Quarterly) | 102.71M |
| Free Cash Flow to Firm (Quarterly) | 119.57M |
| Free Cash Flow Yield | 2.39% |